Loading...
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). The availability of several EGFR tyrosine kinase inhibitors approved for use in the first-line or later settings in N...
Saved in:
| Published in: | J Oncol Pharm Pract |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448811/ https://ncbi.nlm.nih.gov/pubmed/32567494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220931926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|